STOCK TITAN
  1. Home
  2. News
  3. CLDX

Celldex Therapeutics Inc. - CLDX STOCK NEWS

Welcome to our dedicated news page for Celldex Therapeutics (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celldex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celldex Therapeutics's position in the market.

News
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on March 11, 2024. The webcast will be available on the company's website, with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
-
News
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) announces CEO participation in an 'Inflammation & Immunology Corporate Panel Discussion' at TD Cowen's 44th Annual Health Care Conference. The panel will be live webcasted on March 5, 2024, from 2:10 to 3:10 PM ET, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
News
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Celldex Therapeutics, Inc. successfully closed a public offering of 9,798,000 shares of common stock, raising approximately $460.5 million. The offering price per share was $47.00. The underwriters also exercised their option to purchase an additional 1,278,000 shares. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor were the joint bookrunning managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
offering
News
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at $47.00 per share, expecting to raise approximately $400.4 million. The offering includes a 30-day option for underwriters to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.95%
Tags
offering
-
News
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) plans to offer $250.0 million of common stock in a public offering, with an option for an additional $37.5 million. The proceeds will fund the development of product candidates, including barzolvolimab, and support the company's clinical pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
offering
-
News
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) reported positive Phase 2 CSU data and financial results for Q4 and year-end 2023. Barzolvolimab showed promising results in CSU and CIndU studies, with plans for Phase 3 initiation in summer 2024. The company also introduced CDX-585, a bispecific antibody platform. Financially, Celldex's cash position improved to $423.6 million by December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.76%
Tags
earnings
News
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Rhea-AI Summary
Celldex Therapeutics (CLDX) reports positive 12-week results from Phase 2 trial of barzolvolimab in patients with chronic spontaneous urticaria (CSU), meeting primary and secondary endpoints with significant decreases in disease activity. The treatment showed rapid onset within 2 weeks, favorable safety profile, and similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease. 52-week results and Phase 3 CSU trial initiations expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The webcast will be available on the company's website, with a replay option for 30 days. This event provides an opportunity for investors and stakeholders to gain insights into the company's future plans and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
News
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
Rhea-AI Summary
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the acceptance of an abstract describing 12-week results from the Phase 2 clinical trial of barzolvolimab in patients with chronic spontaneous urticaria (CSU) at the American Academy of Allergy, Asthma & Immunology Annual Meeting 2024. The study showed significant decreases in disease activity and good tolerability. The Company will present the data on February 24 at the conference and host a webcast on February 25 to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
conferences clinical trial
News
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) to participate in fireside chat at Evercore ISI HealthCONx Conference. Webcast and replay details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences
Stock CLDX logo
Celldex Therapeutics Inc.

Nasdaq:CLDX

CLDX Rankings

#1675 Ranked by Market Cap
#4135 Ranked by Stock Gains
N/A Ranked by Dividends

CLDX Stock Data

2.58B
52.74M
0.35%
96.8%
9.98%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Hampton

About CLDX

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im